MEREO BIOPHARMA GROUP PL-ADR Business Summary

Mereo BioPharma Group plc (MREO) is a clinical-stage biopharmaceutical company that operates under a capital-efficient business model, primarily generating revenue through strategic licensing agreements, milestone payments, and potential future royalties. The company specializes in acquiring and developing high-potential assets deprioritized by larger pharmaceutical firms, focusing on two primary business segments: rare diseases and oncology. Its lead clinical programs include setrusumab (UX-143) for osteogenesis imperfecta, developed in partnership with Ultragenyx, and alvelestat (MPH966) for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). Mereo competes directly with rare disease specialists such as Amicus Therapeutics, Abeona Therapeutics, and Avalo Therapeutics. Within this landscape, Mereo occupies a niche as a late-stage developer of orphan drugs, currently navigating the transition from clinical validation to regulatory submission following recent Phase 3 data readouts for its lead assets. The company is led by Co-founder and CEO Dr. Denise Scots-Knight, who brings over 25 years of experience in venture capital and biopharma, including previous leadership roles at Phase4 Partners and senior positions at Amersham and Fisons. The executive team is further bolstered by CFO Christine Fox, Chief Scientific Officer Dr. John Lewicki—formerly CEO of OncoMed Pharmaceuticals—and SVP Dr. Jackie Parkin, who previously led clinical development programs at GlaxoSmithKline. Mereo’s strategic direction is overseen by a board chaired by Dr. Anders Ekblom, a former Executive VP at AstraZeneca, and includes industry veterans like Anne Hyland and Dr. Jeremy Bender. The company maintains a strong institutional investor base, featuring significant holdings from Janus Henderson Group, Rubric Capital Management, and Rock Springs Capital, alongside strategic investment from AstraZeneca.